Glycominds' IBDX panel delivers an indispensable combination of four blood tests based on serological markers, enabling diagnosis of Inflammatory Bowel Disease (IBD). The panel provides the ability to differentiate between patients suffering from IBD and those who are not, as well as between patients with Crohn's Disease and Ulcerative Colitis. Additionally important, the IBDX panel can predict the severity and complications caused by Crohn's Disease (i.e. strictures, fistulas, needand need for surgery…).
What are serological markers?
Serology is a science focused on the characterization of serum - the non-cellular component of blood. Serological markers are implemented as a clinical tool to identify specific diseases in individuals, and are unique indicators of certain biological processes taking place within a person's body. Specific antibodies are usually discovered to be typically present in the blood of patients with different diseases. Glycominds' tests identify and measure the presence of these antibodies in your blood, enabling in the determination of whether or not you may have a certain disease.
Why use serological markers?
Serological marker testing greatly reduces how much time and the number of procedures needed for your physician to be able to accurately diagnosis possible disease. Diagnosis frequently involves a biopsy (removal of a small amount of the intestinal lining).
Serological tests offer physicians an important other tool, which is not an invasive procedure, just requiring a blood sample. Also the tests are relatively inexpensive compared to other diagnostic tools available.
Why use the IBDX panel?
The panel significantly reduces the amount of time, as well as the number of procedures you might undergo until diagnosis confirmation (by biopsy). The IBDX™ - panel features a high degree of sensitivity (the ability to diagnose a condition) while still maintaining high specificity (insuring that people who receive positive results actually have the disease) for IBD differential diagnosis.
The IBDX panel enables earlier diagnosis, compared to current invasive procedures. Early diagnosis can enable you receive earlier and more accurate treatment. Additionally, it has been proved that early diagnosis of IBD can prevent complications, including colon removal in 25% to 40% of Ulcerative Colitis (UC) patients. The IBDX panel can correctly identify 80% of patients with Crohn's Disease (CD). This is higher than any other available blood tests in the market.
Because Crohn's Disease does not have a consistent appearance and varies according to locations, behaviors, severities and activities - it is considered a multifactor disease, and as a result requires a combination of serological markers testing (panel) for a full diagnosis. Glycominds' IBDX panel of serological markers can help your doctor greatly in identifying the exact type of Crohn's disease for any given patient. The panel can predict the severity and complications of CD (strictures, fistulas and the need for surgery) and can be used immediately at disease onset.
How can the IBDX panel help me?
If it is suspected by your physician that you have IBD, your doctor may refer you to have the IBDX panel serology tests performed in your nearest local laboratory . Once your physician receives the results and verifies their diagnosis, he may initiate the proper treatment to ease the symptoms and control the disease outbreaks and symptoms.
Glycominds is committed to continuously discover and develop new, advanced autoimmunity tests which will improve the quality of life for you, your family, and millions of other patients around the world.
2008 Glycominds Ltd. All rights reserved terms of use
